AdvanTIG-205
Completed
Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer
BeOne Study ID
AdvanTIG-205
ClinicalTrials.gov ID
EudraCT or EUCT Number
2021-001075-17
China Drug Trials ID
CTR20212782
Study Overview
Sex: All
Age: 18 Years / N/A
Accepts Healthy Volunteers? No
Study Documents
Plain Language Summary Study Protocol Statistical Analysis PlanStudy Overview
Sex: All
Age: 18 Years / N/A
Accepts Healthy Volunteers? No